Clinical Trial

The KN510713 Study in Combination With mFOLFIRINOX

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-06.
Status change: Not Yet Recruiting → Recruiting 2026-04-07
Trial Details
NCT Number NCT07114861
Lead Sponsor New Cancer Cure-Bio Co.,Ltd.
Conditions Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment 30 participants
Start Date 2025-12-16
Primary Completion 2028-09-22 (estimated)
Study Completion 2028-10-22 (estimated)
Updated on ClinicalTrials.gov 2026-04-13